Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ASP015K

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
Two randomized, double-blind, placebo-controlled studies are reported that had the objective to evaluate the pharmacokinetics… Expand
Is this relevant?
2015
2015
Human mass balance, metabolite profile and identification of metabolic enzymes of [14C]ASP015K, a novel oral janus kinase inhibitor
Abstract 1. The human mass balance of 14C-labelled ASP015K ([14C]ASP015K), an orally bioavailable Janus kinase (JAK) inhibitor… Expand
Is this relevant?
2015
2015
A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to…
BACKGROUND Many immune-mediated disorders, including psoriasis, involve cytokine signalling via Janus kinase (JAK) enzymes… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
In vitro/in vivo investigations to examine the gender differences in the pharmacokinetics of novel oral Janus kinase (JAK) inhibitor ASP015K and sulfate metabolite M2 in rats
Abstract 1. Although marked gender differences have been reported for the exposure level of the sulfate metabolite M2 of ASP015K… Expand
Is this relevant?
2014
2014
OP0149 A Phase 2B Study of an Oral JAK Inhibitor ASP015K Monotherapy in Japanese Patients with Moderate to Severe Rheumatoid Arthritis
Background ASP015K is a novel oral Janus kinase (JAK) inhibitor in development for the treatment of rheumatoid arthritis (RA… Expand
Is this relevant?
2013
2013
AB0363 Coadministration of asp015k, a novel janus kinase inhibitor, with methotrexate demonstrates tolerability and lack of pharmacokinetic interactions in patients with rheumatoid arthritis
Background ASP015K is an oral Janus kinase (JAK) inhibitor with selectivity for JAK1/3 in development for treatment of rheumatoid… Expand
Is this relevant?
2013
2013
THU0101 ASP015K: A Novel Jak Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats
Background The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic… Expand
Is this relevant?
2013
2013
AB0364 Pharmacokinetics, safety, and tolerability of asp015k, a novel janus kinase inhibitor, in healthy volunteers
Background ASP015K is an oral Janus kinase (JAK) inhibitor of JAK1/3 in development for treatment of autoimmune diseases (eg… Expand
Is this relevant?
2013
2013
THU0256 Pharmacodynamics of ASP015K, A Novel Janus Kinase Inhibitor, in Healthy Volunteers
Background ASP015K is an oral Janus kinase (JAK) inhibitor with moderate selectivity for JAK3, a key enzyme for interleukin-2 (IL… Expand
Is this relevant?
2013
2013
THU0227 Pooled Analysis of Clinical Safety Data for ASP015K, a Novel Jak Inhibitor in Development for Treatment of Autoimmune Diseases
Background Janus kinase (JAK) enzymes play key roles in cytokine signaling and are important in the pathology of autoimmune… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE